"In March, it became the world's first invasive brain-computer interface approved for use beyond clinical trials." [world's first invasive brain-computer interface]
The regulatory approval milestone—not just a technical achievement—directly supports the claim that state-sanctioned commercialization is now the mechanism driving national BCI competition.
Reasoning from this article
China's approval of NEO for commercial use represents a structural shift: neurotechnology is transitioning from research curiosity to state-legitimized industry, with regulatory frameworks becoming a competitive weapon. This mirrors how China used regulatory speed in EVs and 5G to leapfrog incumbents. The pattern generalizes: whichever state first normalizes a transformative technology through regulation gains first-mover advantages in standards, talent, and market formation.